Little consistency in evidence cited by commercial plans for specialty drug coverage

5 November 2019 - Recently published research indicates wide variation in the evidence that US commercial health plans reported reviewing ...

Read more →

Advancing patient engagement

2 October 2019 - It’s widely accepted that seeking patient input into their health and care improves outcomes for them and ...

Read more →

How to ensure that novel analytic methods are fit for decision-making

2 October 2019 - The past decade has seen the increased generation and availability of new data sources such as ...

Read more →

Health‐related quality of life in oncology drug reimbursement submissions in Canada: a review of submissions to the pan‐Canadian Oncology Drug Review

23 September 2019 - In Canada, CADTH evaluates and makes recommendations for the reimbursement of cancer drugs. One component of ...

Read more →

When are RCTs required for breakthrough drugs, HDEs? JAMA study investigates

11 September 2019 - A new study in JAMA Network Open finds that drugs and medical devices approved by the ...

Read more →

The use of validated and non-validated surrogate endpoints in two EMA expedited approval pathways: A cross-sectional study of products authorised 2011–2018

10 September 2019 - In situations of unmet medical need or in the interests of public health, expedited approval pathways, ...

Read more →

As value assessment frameworks evolve, are they finally ready for prime time?

9 September 2019 - Value assessment frameworks have emerged as tools to assist health care decision makers in the United States ...

Read more →

Patient Voice Aotearoa calls for PHARMAC reform

28 August 2019 - Patient Voice Aotearoa has launched a petition calling for the Minister of Health to initiate an ...

Read more →

Incorporating affordability concerns within cost-effectiveness analysis for health technology assessment

27 August 2019 - New framework considers the scale, time profile, and uncertainty of budget impacts. ...

Read more →

Pharmacists demand audit over Gliatilin’s insurance benefit

27 August 2019 - A pharmacists’ group demanded an audit against the Ministry of Health and Welfare and the Health ...

Read more →

Developing real-world data and evidence to support regulatory decision-making

26 August 2019 - On 3 October, the FDA and the Duke-Margolis Center for Health Policy will hold a conference, ...

Read more →

Former FDA Commissioners seek to expand use of RWE in regulatory, payment decisions

21 August 2019 - A new report from the Bipartisan Policy Center makes recommendations to expand the use of real-world ...

Read more →

ICER Proposes Updates to 2020 Value Assessment Framework Methods and Procedures

21 August 2019 - Reflecting experience with current framework, benchmarking with other HTA groups, and public input, proposals include new emphasis ...

Read more →

Lack of transparency hampers cancer drug debate

19 August 2019 - The current debate raging over cancer drug funding is emotional, and the different agenda of lobby ...

Read more →

ICER's value framework and patient feedback: Q&A with Steve Pearson

15 August 2019 - ICER invites all patient organizations and the general public to attend a webinar to learn more ...

Read more →